Bristol-Myers Squibb Company (BMY)
Growth Portfolio Will Likely Drive Bristol Myers Squibb's Q2
Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q2 2024 results on Friday, July 26. We expect BMY stock to trade higher, with its revenue and earnings likely exceeding the street estimates.
2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You?
Dividend payers tend to outperform businesses that aren't committed to distributing a portion of earnings to shareholders. Bristol Myers Squibb offers a yield above 5% at recent prices.
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
3 Defensive Stocks to Shield Your Portfolio in July
Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell's recent comments. In his address at the Economic Club of Washington D.C.
Bristol-Myers Squibb - Investors Are Too Long-Term Focused
Bristol-Myers Squibb Company faces challenges with patent expirations and debt from acquisitions, but has strong long-term shareholder return potential. Q1 2024 results show revenue growth and promising regulatory approvals, supporting long-term portfolio growth. The KarXT acquisition and guidance demonstrate commitment to diversification, managing business, and driving future shareholder returns.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $42.39, representing a -1.76% change from its previous close.
Bristol-Myers Squibb Is A Bargain Now
Bristol-Myers Squibb reported first quarter results and had to lower its guidance for fiscal 2024 due to the IPRD acquisition for $12.9 billion. The company will also lose patent protection for Revlimid, Opdivo and Eliquis, which is a huge part of their revenue. But the company is trying to shift its portfolio from its legacy products to its growth products.
Collect $2,000 in Dividends Per Year by Investing $35,000 in These 3 Stocks
Bristol Myers Squibb is down big this year, but with a growth strategy in place, it can make for an appealing contrarian investment. AT&T's business is growing, and its strong free cash flow could pave the way for a rising dividend.
Is Bristol-Myers Squibb's Rich Dividend Yield Worth The Patent Cliff Correction Risk?
Bristol-Myers Squibb continues to underperform the wider market with bullish support yet to materialize, despite the double beat FQ1'24 earnings call, cost-saving strategies, and numerous regulatory wins. With BMY stock seemingly behaving like a falling knife, our previous Buy rating has not panned out well indeed. However, we are reiterating our optimism surrounding BMY's dividend investment thesis and growing in-house/acquired pipelines, with the second half of the decade likely to be promising.
Bristol-Myers Squibb Reports On 7/26 - Options Expire The Same Day
According to NextEarningsDate.com, the Bristol-Myers Squibb next earnings date is projected to be 7/26 before market open, with earnings estimates of $1.53/share on $10.56 Billion of revenue.
